Aldosterone in the pathogenesis of chronic kidney disease and proteinuria

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 303-306

  Lu, Yee ^a   Ku, Elaine ^a   Campese, Vito M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aldosterone; Aldosterone escape; Chronic kidney disease; Mineralocorticoid receptor antagonists; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; PLACEBO; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG TARGETING; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART MUSCLE FIBROSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FIBROSIS; MICROALBUMINURIA; NONHUMAN; PATHOGENESIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM;

EID: 77956263726     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0116-4     Document Type: Review

References (41)

1. B Stengel S Billon PC Van Dijk, et al. 2003 Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999 Nephrol Dial Transplant 18 1824 1833 10.1093/ndt/gfg233 12937231
2. US Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
3. Kotchen TA: Chapter 241. Hypertensive vascular disease. In Harrison's Principles of Internal Medicine, 17th edn. New York: McGraw-Hill; 2011. http://www.accessmedicine.com/content.aspx?aID=2872428.
4. JP Bonvalet N Alfaidy N Farman M Lombes 1995 Aldosterone: intracellular receptors in human heart Eur Heart J 16 Suppl N 92 97 1:CAS:528: DyaK28XitlGlsrg%3D 8682069
5. BL Roland ZS Krozowski JW Funder 1995 Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies Mol Cell Endocrinol 111 R1 R7 10.1016/0303-7207(95)03559-P 1:CAS:528:DyaK2MXlvFKlurw%3D 7649347
6. L Kornel C Ramsay N Kanamarlapudi, et al. 1982 Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids Clin Exp Hypertens A 4 1561 1582 10.3109/10641968209061625 1:STN:280:DyaL3s%2FltFGhtw%3D%3D 7139970
7. KT Weber P Anversa PW Armstrong, et al. 1992 Remodeling and reparation of the cardiovascular system J Am Coll Cardiol 20 3 16 10.1016/0735-1097(92)90130- F 1:STN:280:DyaK383pvFyntQ%3D%3D 1318886
8. NJ Brown MA Agirbasli GH Williams, et al. 1998 Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 Hypertension 32 965 971 1:CAS:528:DyaK1MXitVWjsA%3D%3D 9856958
9. NJ Brown KS Kim YQ Chen, et al. 2000 Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production J Clin Endocrinol Metab 85 336 344 10.1210/jc.85.1.336 1:CAS:528: DC%2BD3cXjtl2lsw%3D%3D 10634408
10. Y Sun J Zhang JQ Zhang FJ Ramires 2000 Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats Hypertension 35 1078 1084 1:CAS:528:DC%2BD3cXjvV2qtr4%3D 10818068
11. M Epstein 2001 Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift J Hypertens 19 829 842 10.1097/00004872-200105000-00001 1:CAS:528:DC%2BD3MXktVWms7s%3D 11393664
12. ME Ullian JR Schelling SL Linas 1992 Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses Hypertension 20 67 73 1:CAS:528:DyaK38XkvVeltrY%3D 1618554
13. CS Barr CC Lang J Hanson, et al. 1995 Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease Am J Cardiol 76 1259 1265 10.1016/S0002-9149(99)80353-1 1:CAS:528:DyaK28Xkt1altA%3D%3D 7503007
14. MA Weber RE Purdy 1982 Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle Life Sci 30 2009 2017 10.1016/0024- 3205(82)90441-6 1:CAS:528:DyaL38XktFOmsLg%3D 7109834
15. S Arima K Kohagura HL Xu, et al. 2003 Nongenomic vascular action of aldosterone in the glomerular microcirculation J Am Soc Nephrol 14 2255 2263 10.1097/01.ASN.0000083982.74108.54 1:CAS:528:DC%2BD3sXmtl2lur4%3D 12937301
16. M Nagase S Shibata S Yoshida, et al. 2006 Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker Hypertension 47 1084 1093 10.1161/01.HYP.0000222003.28517.99 1:CAS:528:DC%2BD28XksVOmu7g%3D 16636193
17. B Pitt F Zannad WJ Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D 10471456
18. RS McKelvie S Yusuf D Pericak, et al. 1999 Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study The RESOLVD Pilot Study Investigators. Circulation 100 1056 1064 1:CAS:528:DyaK1MXmt1Whs7w%3D
19. M Cicoira L Zanolla L Franceschini, et al. 2002 Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 89 403 407 10.1016/S0002-9149(01)02261-5 1:CAS:528:DC%2BD38XhtVKlurc%3D 11835920
20. J Lakkis WX Lu MR Weir 2003 RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease Curr Hypertens Rep 5 408 417 10.1007/s11906-003-0087-9 12948434
21. T Berl FH Katz WL Henrich, et al. 1978 Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure Kidney Int 14 228 235 10.1038/ki.1978.114 1:STN:280:DyaE1M%2FntFWksA%3D%3D 723150
22. RJ Hene P Boer HA Koomans EJ Mees 1982 Plasma aldosterone concentrations in chronic renal disease Kidney Int 21 98 101 10.1038/ki.1982.14 1:STN:280:DyaL387ptlamtA%3D%3D 7043053
23. P Lijnen J Staessen R Fagard A Amery 1982 Increase in plasma aldosterone during prolonged captopril treatment Am J Cardiol 49 1561 1563 10.1016/0002-9149(82)90390-3 1:STN:280:DyaL387nvFeguw%3D%3D 7041598
24. KJ Schjoedt S Andersen P Rossing, et al. 2004 Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate Diabetologia 47 1936 1939 10.1007/s00125-004-1542-0 1:CAS:528:DC%2BD2cXhtVOqs7vJ 15551047
25. ZY Quan M Walser GS Hill 1992 Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level Kidney Int 41 326 333 10.1038/ki.1992.45 1:CAS:528:DyaK38XksVSkt7w%3D 1552706
26. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
27. R Rocha PN Chander A Zuckerman CT Stier Jr 1999 Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats Hypertension 33 232 237 1:CAS:528:DyaK1MXht1Ggs70%3D 9931110
28. EL Greene S Kren TH Hostetter 1996 Role of aldosterone in the remnant kidney model in the rat J Clin Invest 98 1063 1068 10.1172/JCI118867 1:CAS:528:DyaK28XlsFOgt7Y%3D 8770880
29. H Goldblatt J Lynch 1934 Hanzal RF Summerville WW: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59 347 379 1:STN:280:DC%2BC3crjs1Wjug%3D%3D
30. A Nicoletti D Heudes N Hinglais, et al. 1995 Left ventricular fibrosis in renovascular hypertensive rats Effect of losartan and spironolactone. Hypertension 26 101 111 1:CAS:528:DyaK2MXnsF2lur0%3D
31. JC Aldigier T Kanjanbuch LJ Ma, et al. 2005 Regression of existing glomerulosclerosis by inhibition of aldosterone J Am Soc Nephrol 16 3306 3314 10.1681/ASN.2004090804 1:CAS:528:DC%2BD2MXht1Cnsr3M 16192423
32. A Sato K Hayashi M Naruse T Saruta 2003 Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 64 68 10.1161/01.HYP.0000044937.95080.E9 1:CAS:528:DC%2BD38Xps1Ohu74%3D 12511531
33. A Sato K Hayashi T Saruta 2005 Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease Am J Hypertens 18 44 49 10.1016/j.amjhyper.2004.06.029 1:CAS:528:DC%2BD2MXit1Wms78%3D 15691616
34. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58(3):1219-1227.
35. K Nitta K Uchida H Nihei 2004 Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases Am J Med 117 444 445 10.1016/j.amjmed. 2004.04.020 15380506
36. RJ MacFadyen AF Lee JJ Morton, et al. 1999 How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82 57 61 1:STN:280:DyaK1MzgslGmug%3D%3D 10377310
37. M Epstein 2006 Aldosterone blockade: an emerging strategy for abrogating progressive renal disease Am J Med 119 912 919 10.1016/j.amjmed.2006.03.038 1:CAS:528:DC%2BD28XhtFertb3F 17071154
38. G Remuzzi T Bertani 1998 Pathophysiology of progressive nephropathies N Engl J Med 339 1448 1456 10.1056/NEJM199811123392007 1:CAS:528: DyaK1cXnsFCqt70%3D 9811921
39. M Epstein GH Williams M Weinberger, et al. 2006 Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 940 951 10.2215/CJN.00240106 1:CAS:528: DC%2BD28XpvFOqsLk%3D 17699311
40. MP Ponda TH Hostetter 2006 Aldosterone antagonism in chronic kidney disease Clin J Am Soc Nephrol 1 668 677 10.2215/CJN.00120106 1:CAS:528:DC%2BD28XnsVWiurg%3D 17699271
41. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.